Society for Hematopathology/European Association for Haematopathology
October 24-26, 2013
Progress in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia: Classification and Molecular Pathogenesis
Robert C. Hickey Auditorium
Floor 11, R. Lee Clark Clinic, 1515 Holcombe Boulevard
The University of Texas MD Anderson Cancer Center
- Conference Brochure
- Conference Agenda
- Case Requirements
- Committee and Faculty
- Registration Information
- Hotel & Transportation Information
- Houston Visitor Information
- Directions to MD Anderson
Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL), represent a heterogeneous group of malignancies that present unique challenges to pathologists. AML can also arise from MDS or myeloproliferative neoplasms and the genetic mechanisms of transformation are largely unknown. The advent of molecular diagnostics has heralded an explosion in new prognostic markers and many new entities were described in the recently published World Health Organization (WHO) classification of neoplasms of the hematopoietic system. Combined with sequencing and proteomic profiling, these technologies have helped identify new targets and signaling pathways, and may soon help to identify individual patients likely to benefit from specific therapies. Thus, this activity is designed to bring the spectrum of hematopoietic diseases to a forum for updating diagnostic criteria, pathophysiologic mechanisms and discussion. A unique aspect of this workshop is that we anticipate participation of expert hematopathologists, hematologists and oncologists from around the world.
After attending the conference, participants should be able to
- Appraise current WHO categories, and identify areas of diagnostic difficulty (Knowledge, Competence, Performance);
- Correlate the advances in molecular diagnostics and the molecular pathogenesis of these tumors (Knowledge, Competence);
- Connect new clinical approaches to treatment and monitoring of patients with AML, MDS and ALL to hematopathology practice (Knowledge, Competence, Performance, Patient Outcomes).
The course is designed for physicians and other health professionals in hematopathology, pathology, hematology and oncology.
Lectures - Case Studies - Questions and Answers - Audience Response System
A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance Verification Certificates
Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants as they depart the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.
Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
The University of Texas MD Anderson Cancer Center Department of Hematopathology is approved by the American Board of Pathology (ABP) to provide Self-Assessment Module (SAM) credits. SAM credits are necessary to meet the ABP maintenance of certification requirements. SAM credits will be available for this conference.